Matthew McClure has been appointed executive vice president and chief medical officer of South San Francisco-based Aligos Therapeutics. He was most recently the chief medical officer of Second Genome. McClure’s experience also includes time at InterMune, which was acquired by Roche in 2014. Preclinical-stage Aligos is developing treatments for liver diseases and viral infections.
Sponsored · Webinar
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX
Sponsored · Special Report
Hyperinflation in rents is over
Hughes Marino
Sponsored · Video
A Fireside Chat with Medpace's Regulatory Affairs Director David Horton
Medpace
